Back to search results

Relacorilant with other treatments for gynecological cancers

This study is testing a drug called relacorilant in combination with other treatments for gynecological cancers, including ovarian, fallopian tube, peritoneal, and endometrial cancers. Researchers want to see how well relacorilant works and if it is safe when given with nab-paclitaxel and bevacizumab. You might be able to join if you are a woman aged 18 or older with one of these cancers. For some, your cancer must be platinum-resistant, or platinum-sensitive but progressed after PARP inhibitor treatment. The main goal is to see how long patients live without their cancer growing or spreading (Progression-Free Survival), measured for up to 18 months. This study is currently recruiting about 270 participants.

Study design
This is a Phase 2, open-label study with multiple treatment groups. It is designed to allow for new treatment groups to be added over time.
What's involved
You would receive relacorilant orally once daily for three days around your nab-paclitaxel infusions. Nab-paclitaxel and bevacizumab are given intravenously (into a vein) on specific days within a 28-day cycle. Treatment continues until your cancer progresses, side effects become too severe, or other reasons for stopping treatment are met.
Compensation
Not stated in the trial record.
Follow-up
Your Progression-Free Survival will be measured from your first dose until your cancer progresses or you pass away, for up to 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06906341

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Recruiting
PHASE2Ages 18+InterventionalTreatment
Corcept Therapeutics
~270 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:Relacorilant 150 mg once daily (QD)Nab-paclitaxel 80 mg/m^2Bevacizumab 10 mg/kg

At a glance

Recruiting sites
49 of 49 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression-Free Survival (PFS)
Measured over Date of first dose until PD or death, up to 18 months

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms
Endometrial Cancer

Explore related trials

Endometrial CarcinomaFallopian Tube CarcinomaMalignant Ovarian NeoplasmPeritoneal Neoplasm

Where it's being run

49 sites across 23 states
Italy7
France6
Spain5
Belgium4
Florida3
Germany3
California2
Missouri2

Study leadership

  • Danny Nguyen, MD · STUDY_DIRECTOR · Corcept Therapeutics

Who to contact

Corcept Therapeutics
[email protected]
650-414-2314
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
Arm A Only: Platinum-resistant disease
Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
Life expectancy of ≥3 months
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Able to swallow and retain oral medication
1 to 3 lines of prior systemic anticancer therapy
Adequate organ function
Negative pregnancy test for patients of childbearing potential
Stage III or IV, recurrent, or metastatic endometrial cancer
Life expectancy of ≥3 months
ECOG performance status of 0 or 1
Able to swallow and retain oral medication
Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD\[L\]1) antibody
1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
Adequate organ function
Negative pregnancy test for patients of childbearing potential

Exclusion

Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
Prior enrollment in a clinical trial of relacorilant
Prior anticancer therapy related toxicities not resolved to grade ≤1
Any surgery within 4 weeks prior to enrollment
Wide-field radiation to more than 25% of marrow-bearing areas
Medical conditions requiring chronic or frequent treatment with corticosteroids
Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
Peripheral neuropathy from any cause \>Grade 1
Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
Bowel obstruction ≤12 weeks prior to study entry
Ascites or pleural effusions requiring therapeutic paracentesis
Untreated or symptomatic central nervous system metastases
History of other malignancy within 3 years prior to enrollment
Has received a live vaccine within 30 days prior to the study start date
Has progressed while receiving weekly paclitaxel or nab-paclitaxel
Prior enrollment in a clinical trial of relacorilant
Prior anticancer therapy related toxicities not resolved to grade ≤1
Any surgery within 4 weeks prior to enrollment
Wide-field radiation to more than 25% of marrow-bearing areas
Medical conditions requiring chronic or frequent treatment with corticosteroids
Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
Peripheral neuropathy from any cause \>Grade 1
Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
Bowel obstruction ≤12 weeks prior to study entry
Ascites or pleural effusions requiring therapeutic paracentesis
History of other malignancy within 3 years prior to enrollment
Has received a live vaccine within 30 days prior to the study start date
Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.

What this trial measures

  • Progression-Free Survival (PFS)Date of first dose until PD or death, up to 18 months

    To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.